Abstract
OBJECTIVE: Allo-HSCT is a well-established treatment for several hematological malignancies. Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a significant problem and is associated with a poor prognosis and low overall survival. Chimerism analysis is one of the tools applied in post-transplant monitoring, as an increasing fraction of recipient cells after HSCT has been linked to a higher risk of relapse. STUDY DESIGN: In this retrospective, single-centre study we have analysed the data of patients treated with allo-HSCT for a range of hematological malignancies in the Department of Paediatric Haematology, Oncology and Transplantology, Medical University of Lublin, Poland, between years 2002-2018. RESULTS: For all 103 patients 3-years OS was 72.6 (95% CI: 64.3-82.0) and 3-years EFS was 72.0 (95% CI: 63.5-81.6). There were no differences in 3-years OS and EFS in group of patients who achieved FDC <14 and >14 days: 67.9 (95% CI: 57.4-80.3) vs 81.9 (95% CI: 69.7-96.2), p = 0.220 and 66.0 (95% CI: 55.3-78.7) vs 84.1 (95% CI: 72.3-97.9), p = 0.073, respectively. Early FDC achievement was not significantly associated with risk of relapse, p = 0.181. Based on multivariate Cox regression analysis AML/MDS increased risk of relapse 3x compared to ALL, HR = 2.72, CI95 [1.24-5.98], p = 0.013; PB/CB increased the risk nearly 3x compared to cells from BM, HR = 2.52, CI95 [1.12-5.65], p = 0.025. CONCLUSION: In presented study, achieving early FDC was not associated with lower risk of relapse and had no impact on overall and event-free survival. However, the study presents a unique data of very early chimerism in a large cohort of paediatric patients with haematological malignancies treated within a single unit. Possible extensions to this study, to include analysing more data from a larger patient cohort, may allow us to determine the exact prognostic value of very early chimerism analysis to establish relevant cutoff values and risk thresholds for intervention.